Nektar Therapeutics (NKTR) Posts Q3 Loss of $0.21, Sales Top Expectations
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
EPS Growth %: +26.6%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CRWS, MEI, PODC, More
EPS Growth %: +26.6%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $15.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
